nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxylamine—Benzphetamine—obesity	0.531	1	CrCtD
Doxylamine—Toremifene—Benzphetamine—obesity	0.0362	0.106	CrCrCtD
Doxylamine—Isopropamide—Benzphetamine—obesity	0.0288	0.0845	CrCrCtD
Doxylamine—Tamoxifen—Benzphetamine—obesity	0.0249	0.0731	CrCrCtD
Doxylamine—Methadyl Acetate—Benzphetamine—obesity	0.0241	0.0707	CrCrCtD
Doxylamine—Levomethadyl Acetate—Benzphetamine—obesity	0.0241	0.0707	CrCrCtD
Doxylamine—Cyclobenzaprine—Benzphetamine—obesity	0.0226	0.0665	CrCrCtD
Doxylamine—Dextropropoxyphene—Benzphetamine—obesity	0.0197	0.058	CrCrCtD
Doxylamine—Tripelennamine—Benzphetamine—obesity	0.0188	0.0553	CrCrCtD
Doxylamine—Atomoxetine—Benzphetamine—obesity	0.0188	0.0553	CrCrCtD
Doxylamine—Bromodiphenhydramine—Benzphetamine—obesity	0.0176	0.0517	CrCrCtD
Doxylamine—Benzphetamine—Methamphetamine—obesity	0.0174	0.0512	CrCrCtD
Doxylamine—Pheniramine—Benzphetamine—obesity	0.0172	0.0506	CrCrCtD
Doxylamine—Methadone—Benzphetamine—obesity	0.0165	0.0485	CrCrCtD
Doxylamine—Clofedanol—Benzphetamine—obesity	0.0143	0.042	CrCrCtD
Doxylamine—Orphenadrine—Benzphetamine—obesity	0.0138	0.0406	CrCrCtD
Doxylamine—Promazine—Benzphetamine—obesity	0.0132	0.0388	CrCrCtD
Doxylamine—Diphenhydramine—Benzphetamine—obesity	0.0123	0.0361	CrCrCtD
Doxylamine—Atomoxetine—NPY1R—obesity	0.0003	0.123	CrCbGaD
Doxylamine—Diplopia—Bupropion—obesity	0.000221	0.00247	CcSEcCtD
Doxylamine—Sweating increased—Orlistat—obesity	0.000221	0.00246	CcSEcCtD
Doxylamine—Dyspnoea—Diethylpropion—obesity	0.000219	0.00244	CcSEcCtD
Doxylamine—Somnolence—Diethylpropion—obesity	0.000218	0.00243	CcSEcCtD
Doxylamine—Affect lability—Bupropion—obesity	0.000218	0.00243	CcSEcCtD
Doxylamine—Abdominal discomfort—Orlistat—obesity	0.000217	0.00242	CcSEcCtD
Doxylamine—Hypersensitivity—Phenylpropanolamine—obesity	0.000217	0.00242	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Diethylpropion—obesity	0.000212	0.00236	CcSEcCtD
Doxylamine—Irritability—Bupropion—obesity	0.000211	0.00236	CcSEcCtD
Doxylamine—Lacrimation increased—Topiramate—obesity	0.000211	0.00235	CcSEcCtD
Doxylamine—Urinary retention—Bupropion—obesity	0.000211	0.00235	CcSEcCtD
Doxylamine—Constipation—Diethylpropion—obesity	0.00021	0.00234	CcSEcCtD
Doxylamine—Mood swings—Bupropion—obesity	0.00021	0.00234	CcSEcCtD
Doxylamine—Somnolence—Cimetidine—obesity	0.000208	0.00231	CcSEcCtD
Doxylamine—Dehydration—Bupropion—obesity	0.000206	0.0023	CcSEcCtD
Doxylamine—Nausea—Phendimetrazine—obesity	0.000205	0.00229	CcSEcCtD
Doxylamine—Asthenia—Phentermine—obesity	0.000202	0.00226	CcSEcCtD
Doxylamine—Feeling abnormal—Diethylpropion—obesity	0.000202	0.00226	CcSEcCtD
Doxylamine—Orthostatic hypotension—Bupropion—obesity	0.000202	0.00225	CcSEcCtD
Doxylamine—Depression—Orlistat—obesity	0.000202	0.00225	CcSEcCtD
Doxylamine—Fatigue—Cimetidine—obesity	0.000201	0.00225	CcSEcCtD
Doxylamine—Breast disorder—Bupropion—obesity	0.0002	0.00223	CcSEcCtD
Doxylamine—Constipation—Cimetidine—obesity	0.0002	0.00223	CcSEcCtD
Doxylamine—Cramp muscle—Bupropion—obesity	0.000199	0.00222	CcSEcCtD
Doxylamine—Nasopharyngitis—Bupropion—obesity	0.000198	0.00221	CcSEcCtD
Doxylamine—Depression—Sibutramine—obesity	0.000195	0.00218	CcSEcCtD
Doxylamine—Urticaria—Diethylpropion—obesity	0.000195	0.00217	CcSEcCtD
Doxylamine—Dizziness—Phenylpropanolamine—obesity	0.000195	0.00217	CcSEcCtD
Doxylamine—Diarrhoea—Phentermine—obesity	0.000193	0.00215	CcSEcCtD
Doxylamine—Feeling abnormal—Cimetidine—obesity	0.000193	0.00215	CcSEcCtD
Doxylamine—Bronchospasm—Bupropion—obesity	0.000188	0.0021	CcSEcCtD
Doxylamine—Sweating—Sibutramine—obesity	0.000188	0.00209	CcSEcCtD
Doxylamine—Pancreatitis—Bupropion—obesity	0.000188	0.00209	CcSEcCtD
Doxylamine—Vomiting—Phenylpropanolamine—obesity	0.000188	0.00209	CcSEcCtD
Doxylamine—Dizziness—Phentermine—obesity	0.000187	0.00208	CcSEcCtD
Doxylamine—Sweating increased—Bupropion—obesity	0.000186	0.00208	CcSEcCtD
Doxylamine—Rash—Phenylpropanolamine—obesity	0.000186	0.00207	CcSEcCtD
Doxylamine—Dermatitis—Phenylpropanolamine—obesity	0.000186	0.00207	CcSEcCtD
Doxylamine—Abdominal discomfort—Bupropion—obesity	0.000183	0.00204	CcSEcCtD
Doxylamine—Pancytopenia—Bupropion—obesity	0.000182	0.00203	CcSEcCtD
Doxylamine—Hepatitis—Orlistat—obesity	0.000182	0.00202	CcSEcCtD
Doxylamine—Vomiting—Phentermine—obesity	0.000179	0.002	CcSEcCtD
Doxylamine—Urinary tract disorder—Orlistat—obesity	0.000179	0.002	CcSEcCtD
Doxylamine—Bradycardia—Sibutramine—obesity	0.000179	0.00199	CcSEcCtD
Doxylamine—Urethral disorder—Orlistat—obesity	0.000178	0.00198	CcSEcCtD
Doxylamine—Rash—Phentermine—obesity	0.000178	0.00198	CcSEcCtD
Doxylamine—Dermatitis—Phentermine—obesity	0.000178	0.00198	CcSEcCtD
Doxylamine—Nausea—Phenylpropanolamine—obesity	0.000175	0.00195	CcSEcCtD
Doxylamine—Hypersensitivity—Cimetidine—obesity	0.000172	0.00192	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Bupropion—obesity	0.000169	0.00189	CcSEcCtD
Doxylamine—Diarrhoea—Diethylpropion—obesity	0.000168	0.00187	CcSEcCtD
Doxylamine—Nausea—Phentermine—obesity	0.000168	0.00187	CcSEcCtD
Doxylamine—Asthenia—Cimetidine—obesity	0.000168	0.00187	CcSEcCtD
Doxylamine—Eye disorder—Sibutramine—obesity	0.000164	0.00183	CcSEcCtD
Doxylamine—Immune system disorder—Orlistat—obesity	0.000164	0.00183	CcSEcCtD
Doxylamine—Mediastinal disorder—Orlistat—obesity	0.000164	0.00182	CcSEcCtD
Doxylamine—Sweating—Bupropion—obesity	0.000164	0.00182	CcSEcCtD
Doxylamine—Tamoxifen—CES1—obesity	0.000164	0.0672	CrCbGaD
Doxylamine—Dizziness—Diethylpropion—obesity	0.000162	0.00181	CcSEcCtD
Doxylamine—Polyuria—Topiramate—obesity	0.000161	0.00179	CcSEcCtD
Doxylamine—Diarrhoea—Cimetidine—obesity	0.00016	0.00178	CcSEcCtD
Doxylamine—Immune system disorder—Sibutramine—obesity	0.000159	0.00177	CcSEcCtD
Doxylamine—Vomiting—Diethylpropion—obesity	0.000156	0.00174	CcSEcCtD
Doxylamine—Rash—Diethylpropion—obesity	0.000155	0.00173	CcSEcCtD
Doxylamine—Dermatitis—Diethylpropion—obesity	0.000155	0.00172	CcSEcCtD
Doxylamine—Amitriptyline—NTRK2—obesity	0.000155	0.0635	CrCbGaD
Doxylamine—Dizziness—Cimetidine—obesity	0.000154	0.00172	CcSEcCtD
Doxylamine—Hepatitis—Bupropion—obesity	0.000153	0.00171	CcSEcCtD
Doxylamine—Hallucination—Bupropion—obesity	0.000152	0.0017	CcSEcCtD
Doxylamine—Muscle spasms—Orlistat—obesity	0.000152	0.00169	CcSEcCtD
Doxylamine—Urinary tract disorder—Bupropion—obesity	0.000151	0.00169	CcSEcCtD
Doxylamine—Urethral disorder—Bupropion—obesity	0.00015	0.00167	CcSEcCtD
Doxylamine—Vomiting—Cimetidine—obesity	0.000149	0.00166	CcSEcCtD
Doxylamine—Rash—Cimetidine—obesity	0.000147	0.00164	CcSEcCtD
Doxylamine—Dermatitis—Cimetidine—obesity	0.000147	0.00164	CcSEcCtD
Doxylamine—Muscle spasms—Sibutramine—obesity	0.000147	0.00164	CcSEcCtD
Doxylamine—Ill-defined disorder—Orlistat—obesity	0.000147	0.00163	CcSEcCtD
Doxylamine—Nausea—Diethylpropion—obesity	0.000146	0.00163	CcSEcCtD
Doxylamine—Erythema multiforme—Bupropion—obesity	0.000145	0.00161	CcSEcCtD
Doxylamine—Angioedema—Orlistat—obesity	0.000144	0.00161	CcSEcCtD
Doxylamine—Tremor—Sibutramine—obesity	0.000143	0.0016	CcSEcCtD
Doxylamine—Eye disorder—Bupropion—obesity	0.000143	0.0016	CcSEcCtD
Doxylamine—Malaise—Orlistat—obesity	0.000143	0.00159	CcSEcCtD
Doxylamine—Cardiac disorder—Bupropion—obesity	0.000142	0.00158	CcSEcCtD
Doxylamine—Flushing—Bupropion—obesity	0.000142	0.00158	CcSEcCtD
Doxylamine—Vertigo—Orlistat—obesity	0.000142	0.00158	CcSEcCtD
Doxylamine—Ill-defined disorder—Sibutramine—obesity	0.000142	0.00158	CcSEcCtD
Doxylamine—Diplopia—Topiramate—obesity	0.000141	0.00157	CcSEcCtD
Doxylamine—Agitation—Sibutramine—obesity	0.000141	0.00157	CcSEcCtD
Doxylamine—Angioedema—Sibutramine—obesity	0.00014	0.00156	CcSEcCtD
Doxylamine—Palpitations—Orlistat—obesity	0.00014	0.00156	CcSEcCtD
Doxylamine—Affect lability—Topiramate—obesity	0.000139	0.00155	CcSEcCtD
Doxylamine—Nausea—Cimetidine—obesity	0.000139	0.00155	CcSEcCtD
Doxylamine—Immune system disorder—Bupropion—obesity	0.000138	0.00154	CcSEcCtD
Doxylamine—Mediastinal disorder—Bupropion—obesity	0.000138	0.00154	CcSEcCtD
Doxylamine—Malaise—Sibutramine—obesity	0.000138	0.00154	CcSEcCtD
Doxylamine—Vertigo—Sibutramine—obesity	0.000137	0.00153	CcSEcCtD
Doxylamine—Convulsion—Orlistat—obesity	0.000137	0.00153	CcSEcCtD
Doxylamine—Leukopenia—Sibutramine—obesity	0.000137	0.00153	CcSEcCtD
Doxylamine—Palpitations—Sibutramine—obesity	0.000135	0.00151	CcSEcCtD
Doxylamine—Irritability—Topiramate—obesity	0.000135	0.0015	CcSEcCtD
Doxylamine—Urinary retention—Topiramate—obesity	0.000134	0.0015	CcSEcCtD
Doxylamine—Anxiety—Orlistat—obesity	0.000134	0.00149	CcSEcCtD
Doxylamine—Mood swings—Topiramate—obesity	0.000134	0.00149	CcSEcCtD
Doxylamine—Discomfort—Orlistat—obesity	0.000133	0.00148	CcSEcCtD
Doxylamine—Convulsion—Sibutramine—obesity	0.000133	0.00148	CcSEcCtD
Doxylamine—Dry mouth—Orlistat—obesity	0.000132	0.00147	CcSEcCtD
Doxylamine—Dehydration—Topiramate—obesity	0.000131	0.00146	CcSEcCtD
Doxylamine—Anxiety—Sibutramine—obesity	0.00013	0.00145	CcSEcCtD
Doxylamine—Anaphylactic shock—Orlistat—obesity	0.000129	0.00144	CcSEcCtD
Doxylamine—Orthostatic hypotension—Topiramate—obesity	0.000129	0.00144	CcSEcCtD
Doxylamine—Discomfort—Sibutramine—obesity	0.000129	0.00143	CcSEcCtD
Doxylamine—Muscle spasms—Bupropion—obesity	0.000128	0.00143	CcSEcCtD
Doxylamine—Breast disorder—Topiramate—obesity	0.000127	0.00142	CcSEcCtD
Doxylamine—Dry mouth—Sibutramine—obesity	0.000127	0.00142	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Topiramate—obesity	0.000127	0.00142	CcSEcCtD
Doxylamine—Nervous system disorder—Orlistat—obesity	0.000126	0.00141	CcSEcCtD
Doxylamine—Nasopharyngitis—Topiramate—obesity	0.000126	0.00141	CcSEcCtD
Doxylamine—Confusional state—Sibutramine—obesity	0.000126	0.0014	CcSEcCtD
Doxylamine—Tremor—Bupropion—obesity	0.000125	0.00139	CcSEcCtD
Doxylamine—Anaphylactic shock—Sibutramine—obesity	0.000125	0.00139	CcSEcCtD
Doxylamine—Hyperhidrosis—Orlistat—obesity	0.000125	0.00139	CcSEcCtD
Doxylamine—Disopyramide—SLC22A1—obesity	0.000124	0.0509	CrCbGaD
Doxylamine—Ill-defined disorder—Bupropion—obesity	0.000124	0.00138	CcSEcCtD
Doxylamine—Agitation—Bupropion—obesity	0.000123	0.00137	CcSEcCtD
Doxylamine—Thrombocytopenia—Sibutramine—obesity	0.000122	0.00136	CcSEcCtD
Doxylamine—Angioedema—Bupropion—obesity	0.000122	0.00136	CcSEcCtD
Doxylamine—Tachycardia—Sibutramine—obesity	0.000122	0.00136	CcSEcCtD
Doxylamine—Hyperhidrosis—Sibutramine—obesity	0.000121	0.00135	CcSEcCtD
Doxylamine—Malaise—Bupropion—obesity	0.00012	0.00134	CcSEcCtD
Doxylamine—Vertigo—Bupropion—obesity	0.00012	0.00134	CcSEcCtD
Doxylamine—Pancreatitis—Topiramate—obesity	0.00012	0.00133	CcSEcCtD
Doxylamine—Leukopenia—Bupropion—obesity	0.000119	0.00133	CcSEcCtD
Doxylamine—Anorexia—Sibutramine—obesity	0.000119	0.00133	CcSEcCtD
Doxylamine—Sweating increased—Topiramate—obesity	0.000119	0.00132	CcSEcCtD
Doxylamine—Palpitations—Bupropion—obesity	0.000118	0.00131	CcSEcCtD
Doxylamine—Abdominal discomfort—Topiramate—obesity	0.000117	0.0013	CcSEcCtD
Doxylamine—Insomnia—Orlistat—obesity	0.000117	0.0013	CcSEcCtD
Doxylamine—Hypotension—Sibutramine—obesity	0.000117	0.0013	CcSEcCtD
Doxylamine—Pancytopenia—Topiramate—obesity	0.000116	0.00129	CcSEcCtD
Doxylamine—Convulsion—Bupropion—obesity	0.000116	0.00129	CcSEcCtD
Doxylamine—Anxiety—Bupropion—obesity	0.000113	0.00126	CcSEcCtD
Doxylamine—Insomnia—Sibutramine—obesity	0.000113	0.00126	CcSEcCtD
Doxylamine—Discomfort—Bupropion—obesity	0.000112	0.00125	CcSEcCtD
Doxylamine—Decreased appetite—Orlistat—obesity	0.000112	0.00125	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Orlistat—obesity	0.000111	0.00124	CcSEcCtD
Doxylamine—Dyspnoea—Sibutramine—obesity	0.000111	0.00124	CcSEcCtD
Doxylamine—Fatigue—Orlistat—obesity	0.000111	0.00124	CcSEcCtD
Doxylamine—Dry mouth—Bupropion—obesity	0.000111	0.00124	CcSEcCtD
Doxylamine—Somnolence—Sibutramine—obesity	0.000111	0.00124	CcSEcCtD
Doxylamine—Confusional state—Bupropion—obesity	0.00011	0.00122	CcSEcCtD
Doxylamine—Anaphylactic shock—Bupropion—obesity	0.000109	0.00121	CcSEcCtD
Doxylamine—Decreased appetite—Sibutramine—obesity	0.000109	0.00121	CcSEcCtD
Doxylamine—Depression—Topiramate—obesity	0.000108	0.00121	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Topiramate—obesity	0.000108	0.0012	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Sibutramine—obesity	0.000108	0.0012	CcSEcCtD
Doxylamine—Constipation—Sibutramine—obesity	0.000107	0.00119	CcSEcCtD
Doxylamine—Nervous system disorder—Bupropion—obesity	0.000107	0.00119	CcSEcCtD
Doxylamine—Thrombocytopenia—Bupropion—obesity	0.000107	0.00119	CcSEcCtD
Doxylamine—Feeling abnormal—Orlistat—obesity	0.000106	0.00118	CcSEcCtD
Doxylamine—Tachycardia—Bupropion—obesity	0.000106	0.00118	CcSEcCtD
Doxylamine—Hyperhidrosis—Bupropion—obesity	0.000105	0.00117	CcSEcCtD
Doxylamine—Anorexia—Bupropion—obesity	0.000104	0.00116	CcSEcCtD
Doxylamine—Feeling abnormal—Sibutramine—obesity	0.000103	0.00115	CcSEcCtD
Doxylamine—Urticaria—Orlistat—obesity	0.000102	0.00114	CcSEcCtD
Doxylamine—Toremifene—ESR1—obesity	0.000102	0.042	CrCbGaD
Doxylamine—Hypotension—Bupropion—obesity	0.000102	0.00113	CcSEcCtD
Doxylamine—Agranulocytosis—Topiramate—obesity	0.000101	0.00113	CcSEcCtD
Doxylamine—Bradycardia—Topiramate—obesity	9.93e-05	0.00111	CcSEcCtD
Doxylamine—Urticaria—Sibutramine—obesity	9.92e-05	0.00111	CcSEcCtD
Doxylamine—Insomnia—Bupropion—obesity	9.84e-05	0.0011	CcSEcCtD
Doxylamine—Hepatitis—Topiramate—obesity	9.76e-05	0.00109	CcSEcCtD
Doxylamine—Hallucination—Topiramate—obesity	9.71e-05	0.00108	CcSEcCtD
Doxylamine—Dyspnoea—Bupropion—obesity	9.7e-05	0.00108	CcSEcCtD
Doxylamine—Somnolence—Bupropion—obesity	9.67e-05	0.00108	CcSEcCtD
Doxylamine—Urinary tract disorder—Topiramate—obesity	9.64e-05	0.00107	CcSEcCtD
Doxylamine—Urethral disorder—Topiramate—obesity	9.57e-05	0.00107	CcSEcCtD
Doxylamine—Hypersensitivity—Orlistat—obesity	9.5e-05	0.00106	CcSEcCtD
Doxylamine—Decreased appetite—Bupropion—obesity	9.46e-05	0.00105	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Bupropion—obesity	9.39e-05	0.00105	CcSEcCtD
Doxylamine—Fatigue—Bupropion—obesity	9.38e-05	0.00105	CcSEcCtD
Doxylamine—Constipation—Bupropion—obesity	9.31e-05	0.00104	CcSEcCtD
Doxylamine—Asthenia—Orlistat—obesity	9.25e-05	0.00103	CcSEcCtD
Doxylamine—Erythema multiforme—Topiramate—obesity	9.23e-05	0.00103	CcSEcCtD
Doxylamine—Hypersensitivity—Sibutramine—obesity	9.2e-05	0.00103	CcSEcCtD
Doxylamine—Pruritus—Orlistat—obesity	9.12e-05	0.00102	CcSEcCtD
Doxylamine—Eye disorder—Topiramate—obesity	9.12e-05	0.00102	CcSEcCtD
Doxylamine—Flushing—Topiramate—obesity	9.06e-05	0.00101	CcSEcCtD
Doxylamine—Cardiac disorder—Topiramate—obesity	9.06e-05	0.00101	CcSEcCtD
Doxylamine—Chlorphenamine—SLC22A1—obesity	9.04e-05	0.0371	CrCbGaD
Doxylamine—Feeling abnormal—Bupropion—obesity	8.97e-05	0.001	CcSEcCtD
Doxylamine—Asthenia—Sibutramine—obesity	8.96e-05	0.000998	CcSEcCtD
Doxylamine—Pruritus—Sibutramine—obesity	8.83e-05	0.000984	CcSEcCtD
Doxylamine—Diarrhoea—Orlistat—obesity	8.82e-05	0.000984	CcSEcCtD
Doxylamine—Immune system disorder—Topiramate—obesity	8.81e-05	0.000982	CcSEcCtD
Doxylamine—Mediastinal disorder—Topiramate—obesity	8.79e-05	0.00098	CcSEcCtD
Doxylamine—Urticaria—Bupropion—obesity	8.64e-05	0.000964	CcSEcCtD
Doxylamine—Diarrhoea—Sibutramine—obesity	8.54e-05	0.000952	CcSEcCtD
Doxylamine—Dizziness—Orlistat—obesity	8.53e-05	0.000951	CcSEcCtD
Doxylamine—Erythema—Topiramate—obesity	8.49e-05	0.000947	CcSEcCtD
Doxylamine—Dizziness—Sibutramine—obesity	8.25e-05	0.00092	CcSEcCtD
Doxylamine—Vomiting—Orlistat—obesity	8.2e-05	0.000914	CcSEcCtD
Doxylamine—Muscle spasms—Topiramate—obesity	8.17e-05	0.00091	CcSEcCtD
Doxylamine—Rash—Orlistat—obesity	8.13e-05	0.000906	CcSEcCtD
Doxylamine—Dermatitis—Orlistat—obesity	8.12e-05	0.000906	CcSEcCtD
Doxylamine—Hypersensitivity—Bupropion—obesity	8.02e-05	0.000894	CcSEcCtD
Doxylamine—Tremor—Topiramate—obesity	7.96e-05	0.000887	CcSEcCtD
Doxylamine—Vomiting—Sibutramine—obesity	7.94e-05	0.000885	CcSEcCtD
Doxylamine—Ill-defined disorder—Topiramate—obesity	7.88e-05	0.000879	CcSEcCtD
Doxylamine—Rash—Sibutramine—obesity	7.87e-05	0.000877	CcSEcCtD
Doxylamine—Dermatitis—Sibutramine—obesity	7.86e-05	0.000876	CcSEcCtD
Doxylamine—Asthenia—Bupropion—obesity	7.81e-05	0.00087	CcSEcCtD
Doxylamine—Agitation—Topiramate—obesity	7.81e-05	0.00087	CcSEcCtD
Doxylamine—Pruritus—Bupropion—obesity	7.7e-05	0.000858	CcSEcCtD
Doxylamine—Nausea—Orlistat—obesity	7.66e-05	0.000854	CcSEcCtD
Doxylamine—Malaise—Topiramate—obesity	7.66e-05	0.000854	CcSEcCtD
Doxylamine—Vertigo—Topiramate—obesity	7.63e-05	0.000851	CcSEcCtD
Doxylamine—Leukopenia—Topiramate—obesity	7.6e-05	0.000848	CcSEcCtD
Doxylamine—Levomethadyl Acetate—CYP19A1—obesity	7.51e-05	0.0309	CrCbGaD
Doxylamine—Palpitations—Topiramate—obesity	7.51e-05	0.000837	CcSEcCtD
Doxylamine—Diarrhoea—Bupropion—obesity	7.45e-05	0.00083	CcSEcCtD
Doxylamine—Nausea—Sibutramine—obesity	7.41e-05	0.000826	CcSEcCtD
Doxylamine—Convulsion—Topiramate—obesity	7.36e-05	0.00082	CcSEcCtD
Doxylamine—Anxiety—Topiramate—obesity	7.21e-05	0.000803	CcSEcCtD
Doxylamine—Dizziness—Bupropion—obesity	7.2e-05	0.000802	CcSEcCtD
Doxylamine—Discomfort—Topiramate—obesity	7.15e-05	0.000796	CcSEcCtD
Doxylamine—Dry mouth—Topiramate—obesity	7.07e-05	0.000788	CcSEcCtD
Doxylamine—Confusional state—Topiramate—obesity	6.99e-05	0.000779	CcSEcCtD
Doxylamine—Vomiting—Bupropion—obesity	6.92e-05	0.000771	CcSEcCtD
Doxylamine—Rash—Bupropion—obesity	6.86e-05	0.000765	CcSEcCtD
Doxylamine—Dermatitis—Bupropion—obesity	6.85e-05	0.000764	CcSEcCtD
Doxylamine—Nervous system disorder—Topiramate—obesity	6.8e-05	0.000758	CcSEcCtD
Doxylamine—Thrombocytopenia—Topiramate—obesity	6.79e-05	0.000757	CcSEcCtD
Doxylamine—Tachycardia—Topiramate—obesity	6.77e-05	0.000754	CcSEcCtD
Doxylamine—Hyperhidrosis—Topiramate—obesity	6.7e-05	0.000747	CcSEcCtD
Doxylamine—Tamoxifen—ESR2—obesity	6.63e-05	0.0273	CrCbGaD
Doxylamine—Anorexia—Topiramate—obesity	6.61e-05	0.000737	CcSEcCtD
Doxylamine—Atomoxetine—HTR1B—obesity	6.51e-05	0.0268	CrCbGaD
Doxylamine—Hypotension—Topiramate—obesity	6.48e-05	0.000722	CcSEcCtD
Doxylamine—Nausea—Bupropion—obesity	6.46e-05	0.00072	CcSEcCtD
Doxylamine—Insomnia—Topiramate—obesity	6.27e-05	0.000699	CcSEcCtD
Doxylamine—Dyspnoea—Topiramate—obesity	6.18e-05	0.000689	CcSEcCtD
Doxylamine—Somnolence—Topiramate—obesity	6.16e-05	0.000687	CcSEcCtD
Doxylamine—Diphenhydramine—SLC22A1—obesity	6.13e-05	0.0252	CrCbGaD
Doxylamine—Decreased appetite—Topiramate—obesity	6.03e-05	0.000672	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Topiramate—obesity	5.99e-05	0.000667	CcSEcCtD
Doxylamine—Fatigue—Topiramate—obesity	5.98e-05	0.000666	CcSEcCtD
Doxylamine—Constipation—Topiramate—obesity	5.93e-05	0.000661	CcSEcCtD
Doxylamine—Carbinoxamine—CYP2E1—obesity	5.9e-05	0.0242	CrCbGaD
Doxylamine—Cyclobenzaprine—HTR2A—obesity	5.75e-05	0.0236	CrCbGaD
Doxylamine—Feeling abnormal—Topiramate—obesity	5.71e-05	0.000637	CcSEcCtD
Doxylamine—Urticaria—Topiramate—obesity	5.51e-05	0.000614	CcSEcCtD
Doxylamine—Atomoxetine—HTR2C—obesity	5.31e-05	0.0218	CrCbGaD
Doxylamine—Chlorphenamine—SLC6A4—obesity	5.24e-05	0.0215	CrCbGaD
Doxylamine—Promazine—DRD4—obesity	5.11e-05	0.021	CrCbGaD
Doxylamine—Hypersensitivity—Topiramate—obesity	5.11e-05	0.000569	CcSEcCtD
Doxylamine—Brompheniramine—CYP2E1—obesity	5.11e-05	0.021	CrCbGaD
Doxylamine—Asthenia—Topiramate—obesity	4.97e-05	0.000554	CcSEcCtD
Doxylamine—Pruritus—Topiramate—obesity	4.9e-05	0.000547	CcSEcCtD
Doxylamine—Diarrhoea—Topiramate—obesity	4.74e-05	0.000529	CcSEcCtD
Doxylamine—Imipramine—SLC22A1—obesity	4.63e-05	0.019	CrCbGaD
Doxylamine—Dizziness—Topiramate—obesity	4.58e-05	0.000511	CcSEcCtD
Doxylamine—Tamoxifen—CYP19A1—obesity	4.44e-05	0.0182	CrCbGaD
Doxylamine—Vomiting—Topiramate—obesity	4.41e-05	0.000491	CcSEcCtD
Doxylamine—Methadone—CYP19A1—obesity	4.4e-05	0.0181	CrCbGaD
Doxylamine—Atomoxetine—SLC6A4—obesity	4.4e-05	0.0181	CrCbGaD
Doxylamine—Rash—Topiramate—obesity	4.37e-05	0.000487	CcSEcCtD
Doxylamine—Dermatitis—Topiramate—obesity	4.37e-05	0.000487	CcSEcCtD
Doxylamine—Promazine—DRD1—obesity	4.32e-05	0.0178	CrCbGaD
Doxylamine—Doxepin—HTR2C—obesity	4.16e-05	0.0171	CrCbGaD
Doxylamine—Nausea—Topiramate—obesity	4.12e-05	0.000459	CcSEcCtD
Doxylamine—Tamoxifen—ESR1—obesity	4.09e-05	0.0168	CrCbGaD
Doxylamine—Amitriptyline—HTR1B—obesity	3.95e-05	0.0162	CrCbGaD
Doxylamine—Promazine—HTR2C—obesity	3.7e-05	0.0152	CrCbGaD
Doxylamine—Doxepin—SLC6A4—obesity	3.45e-05	0.0142	CrCbGaD
Doxylamine—Doxepin—DRD2—obesity	3.43e-05	0.0141	CrCbGaD
Doxylamine—Atomoxetine—HTR2A—obesity	3.38e-05	0.0139	CrCbGaD
Doxylamine—Tamoxifen—CYP2E1—obesity	3.31e-05	0.0136	CrCbGaD
Doxylamine—Imipramine—HTR2C—obesity	3.24e-05	0.0133	CrCbGaD
Doxylamine—Amitriptyline—HTR2C—obesity	3.22e-05	0.0132	CrCbGaD
Doxylamine—Orphenadrine—CYP2E1—obesity	3.22e-05	0.0132	CrCbGaD
Doxylamine—Promazine—DRD2—obesity	3.05e-05	0.0125	CrCbGaD
Doxylamine—Imipramine—SLC6A4—obesity	2.68e-05	0.011	CrCbGaD
Doxylamine—Imipramine—DRD2—obesity	2.67e-05	0.011	CrCbGaD
Doxylamine—Amitriptyline—SLC6A4—obesity	2.67e-05	0.011	CrCbGaD
Doxylamine—Amitriptyline—DRD2—obesity	2.65e-05	0.0109	CrCbGaD
Doxylamine—Doxepin—HTR2A—obesity	2.65e-05	0.0109	CrCbGaD
Doxylamine—Imipramine—CYP2E1—obesity	2.57e-05	0.0106	CrCbGaD
Doxylamine—Amitriptyline—CYP2E1—obesity	2.55e-05	0.0105	CrCbGaD
Doxylamine—Promazine—HTR2A—obesity	2.36e-05	0.00968	CrCbGaD
Doxylamine—Imipramine—HTR2A—obesity	2.06e-05	0.00847	CrCbGaD
Doxylamine—Amitriptyline—HTR2A—obesity	2.05e-05	0.00842	CrCbGaD
Doxylamine—Amitriptyline—ALB—obesity	1.4e-05	0.00576	CrCbGaD
Doxylamine—CHRM1—GPCR downstream signaling—ADRB2—obesity	1.21e-05	0.000329	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ADRB3—obesity	1.2e-05	0.000328	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ADRB3—obesity	1.2e-05	0.000327	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GAL—obesity	1.17e-05	0.000321	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GAL—obesity	1.17e-05	0.00032	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—obesity	1.16e-05	0.000318	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—C5AR1—obesity	1.16e-05	0.000317	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—obesity	1.16e-05	0.000317	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—C5AR1—obesity	1.16e-05	0.000316	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—GNB3—obesity	1.15e-05	0.000315	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—GNB3—obesity	1.15e-05	0.000314	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—GNAS—obesity	1.12e-05	0.000306	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—GNAS—obesity	1.12e-05	0.000306	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—ADRB2—obesity	1.1e-05	0.0003	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—ADRB2—obesity	1.09e-05	0.000299	CbGpPWpGaD
Doxylamine—CHRM1—Circadian rythm related genes—IL6—obesity	1.08e-05	0.000296	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—CCL5—obesity	1.07e-05	0.000293	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—CCL5—obesity	1.07e-05	0.000292	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PRKG1—obesity	1.06e-05	0.00029	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCK—obesity	1.06e-05	0.00029	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCK—obesity	1.06e-05	0.000289	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PRKG1—obesity	1.06e-05	0.000289	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—GNB3—obesity	1.05e-05	0.000286	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—GNB3—obesity	1.04e-05	0.000285	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GLP1R—obesity	1.03e-05	0.000283	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—RBP4—obesity	1.03e-05	0.000283	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GLP1R—obesity	1.03e-05	0.000282	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—RBP4—obesity	1.03e-05	0.000282	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—obesity	1.03e-05	0.000281	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—obesity	1.03e-05	0.00028	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—GNAS—obesity	1.02e-05	0.000278	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HRH3—obesity	1.02e-05	0.000278	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCKAR—obesity	1.02e-05	0.000278	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—GNAS—obesity	1.01e-05	0.000277	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HRH3—obesity	1.01e-05	0.000277	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCKAR—obesity	1.01e-05	0.000277	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PRKAR2B—obesity	9.79e-06	0.000268	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PRKAR2B—obesity	9.76e-06	0.000267	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CCL5—obesity	9.74e-06	0.000266	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CCL5—obesity	9.71e-06	0.000265	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PRKCD—obesity	9.66e-06	0.000264	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PRKCD—obesity	9.63e-06	0.000263	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NCF2—obesity	9.46e-06	0.000259	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—HTR2A—obesity	9.45e-06	0.000258	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—C3—obesity	9.44e-06	0.000258	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NCF2—obesity	9.43e-06	0.000258	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—HTR2A—obesity	9.42e-06	0.000258	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—C3—obesity	9.41e-06	0.000257	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NPY—obesity	9.22e-06	0.000252	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NPY—obesity	9.19e-06	0.000251	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—APOC3—obesity	9.16e-06	0.00025	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IAPP—obesity	9.16e-06	0.00025	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—APOC3—obesity	9.13e-06	0.00025	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IAPP—obesity	9.13e-06	0.00025	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—AGT—obesity	8.97e-06	0.000245	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—AGT—obesity	8.94e-06	0.000244	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HTR1B—obesity	8.89e-06	0.000243	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CRH—obesity	8.89e-06	0.000243	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CRH—obesity	8.86e-06	0.000242	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HTR1B—obesity	8.86e-06	0.000242	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SDC1—obesity	8.79e-06	0.00024	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PRKCD—obesity	8.77e-06	0.00024	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SDC1—obesity	8.76e-06	0.00024	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PRKCD—obesity	8.74e-06	0.000239	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—AKR1C3—obesity	8.65e-06	0.000236	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—AKR1C3—obesity	8.62e-06	0.000236	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—HTR2A—obesity	8.58e-06	0.000235	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—C3—obesity	8.57e-06	0.000234	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—HTR2A—obesity	8.56e-06	0.000234	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—C3—obesity	8.54e-06	0.000234	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NPS—obesity	8.43e-06	0.00023	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NPS—obesity	8.4e-06	0.00023	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PRKCB—obesity	8.29e-06	0.000227	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—F2—obesity	8.29e-06	0.000227	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—DRD1—obesity	8.27e-06	0.000226	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HTR2C—obesity	8.27e-06	0.000226	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PRKCB—obesity	8.26e-06	0.000226	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—F2—obesity	8.26e-06	0.000226	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—DRD1—obesity	8.24e-06	0.000225	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HTR2C—obesity	8.24e-06	0.000225	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—AGT—obesity	8.14e-06	0.000223	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—AGT—obesity	8.12e-06	0.000222	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NTRK2—obesity	8.04e-06	0.00022	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NTRK2—obesity	8.02e-06	0.000219	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ADRB1—obesity	8.01e-06	0.000219	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ADRB1—obesity	7.98e-06	0.000218	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CG—obesity	7.93e-06	0.000217	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CG—obesity	7.91e-06	0.000216	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GHRL—obesity	7.84e-06	0.000214	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PARP1—obesity	7.84e-06	0.000214	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PARP1—obesity	7.81e-06	0.000214	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GHRL—obesity	7.81e-06	0.000214	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—DRD4—obesity	7.77e-06	0.000212	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—DRD4—obesity	7.75e-06	0.000212	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—POMC—obesity	7.55e-06	0.000206	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—F2—obesity	7.53e-06	0.000206	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PRKCB—obesity	7.53e-06	0.000206	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—POMC—obesity	7.53e-06	0.000206	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PRKCB—obesity	7.5e-06	0.000205	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—F2—obesity	7.5e-06	0.000205	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CNR1—obesity	7.42e-06	0.000203	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CNR1—obesity	7.4e-06	0.000202	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TCF7L2—obesity	7.29e-06	0.000199	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TCF7L2—obesity	7.27e-06	0.000199	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—AKT2—obesity	7.26e-06	0.000198	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—DRD2—obesity	7.24e-06	0.000198	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—AKT2—obesity	7.23e-06	0.000198	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—DRD2—obesity	7.22e-06	0.000197	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CG—obesity	7.2e-06	0.000197	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CG—obesity	7.18e-06	0.000196	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GCG—obesity	7.17e-06	0.000196	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PTPN1—obesity	7.17e-06	0.000196	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GCG—obesity	7.14e-06	0.000195	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PTPN1—obesity	7.14e-06	0.000195	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CD—obesity	6.97e-06	0.000191	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CD—obesity	6.95e-06	0.00019	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—POMC—obesity	6.86e-06	0.000187	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PRL—obesity	6.84e-06	0.000187	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—POMC—obesity	6.83e-06	0.000187	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PRL—obesity	6.82e-06	0.000186	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—STK11—obesity	6.74e-06	0.000184	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—STK11—obesity	6.72e-06	0.000184	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CCL2—obesity	6.71e-06	0.000183	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CCL2—obesity	6.69e-06	0.000183	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PLG—obesity	6.66e-06	0.000182	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—RHOA—obesity	6.65e-06	0.000182	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PLG—obesity	6.64e-06	0.000182	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—RHOA—obesity	6.63e-06	0.000181	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—AKT2—obesity	6.59e-06	0.00018	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3R1—obesity	6.58e-06	0.00018	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—AKT2—obesity	6.57e-06	0.00018	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3R1—obesity	6.56e-06	0.000179	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FOXO3—obesity	6.5e-06	0.000178	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ADRB2—obesity	6.49e-06	0.000177	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FOXO3—obesity	6.48e-06	0.000177	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ADRB2—obesity	6.47e-06	0.000177	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SOCS1—obesity	6.39e-06	0.000175	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SOCS1—obesity	6.37e-06	0.000174	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CD—obesity	6.33e-06	0.000173	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CD—obesity	6.31e-06	0.000173	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SOCS3—obesity	6.31e-06	0.000172	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SOCS3—obesity	6.29e-06	0.000172	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GNB3—obesity	6.18e-06	0.000169	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GNB3—obesity	6.16e-06	0.000168	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—TYK2—obesity	6.09e-06	0.000166	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CB—obesity	6.08e-06	0.000166	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—TYK2—obesity	6.07e-06	0.000166	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IGF2—obesity	6.07e-06	0.000166	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CB—obesity	6.06e-06	0.000166	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IGF2—obesity	6.05e-06	0.000165	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—RHOA—obesity	6.04e-06	0.000165	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—RHOA—obesity	6.02e-06	0.000165	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GNAS—obesity	6.01e-06	0.000164	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GNAS—obesity	6e-06	0.000164	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3R1—obesity	5.98e-06	0.000163	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3R1—obesity	5.96e-06	0.000163	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—APOB—obesity	5.89e-06	0.000161	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—APOB—obesity	5.87e-06	0.00016	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCL5—obesity	5.75e-06	0.000157	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCL5—obesity	5.73e-06	0.000157	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—LPL—obesity	5.62e-06	0.000154	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—LPL—obesity	5.61e-06	0.000153	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—FOXO1—obesity	5.58e-06	0.000153	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—RPS6KB1—obesity	5.57e-06	0.000152	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—FOXO1—obesity	5.57e-06	0.000152	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—RPS6KB1—obesity	5.56e-06	0.000152	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CB—obesity	5.52e-06	0.000151	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CB—obesity	5.5e-06	0.00015	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PRKCD—obesity	5.18e-06	0.000142	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PRKCD—obesity	5.17e-06	0.000141	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HTR2A—obesity	5.07e-06	0.000139	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—C3—obesity	5.06e-06	0.000138	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HTR2A—obesity	5.05e-06	0.000138	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—C3—obesity	5.05e-06	0.000138	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IRS2—obesity	4.82e-06	0.000132	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—AGT—obesity	4.81e-06	0.000132	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IRS2—obesity	4.8e-06	0.000131	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—AGT—obesity	4.8e-06	0.000131	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—LEP—obesity	4.71e-06	0.000129	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—APOE—obesity	4.71e-06	0.000129	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—LEP—obesity	4.7e-06	0.000128	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—APOE—obesity	4.7e-06	0.000128	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CAV1—obesity	4.67e-06	0.000128	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—APOA1—obesity	4.66e-06	0.000127	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CAV1—obesity	4.66e-06	0.000127	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—APOA1—obesity	4.65e-06	0.000127	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ESR1—obesity	4.5e-06	0.000123	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ESR1—obesity	4.49e-06	0.000123	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PRKCB—obesity	4.45e-06	0.000122	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—F2—obesity	4.45e-06	0.000122	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PRKCB—obesity	4.43e-06	0.000121	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—F2—obesity	4.43e-06	0.000121	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—BAD—obesity	4.39e-06	0.00012	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—BAD—obesity	4.38e-06	0.00012	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CG—obesity	4.25e-06	0.000116	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CG—obesity	4.24e-06	0.000116	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IRS1—obesity	4.21e-06	0.000115	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IRS1—obesity	4.19e-06	0.000115	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—POMC—obesity	4.05e-06	0.000111	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—POMC—obesity	4.04e-06	0.00011	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—INS—obesity	4.03e-06	0.00011	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—INS—obesity	4.01e-06	0.00011	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCL2—obesity	3.96e-06	0.000108	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCL2—obesity	3.95e-06	0.000108	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IGF1—obesity	3.9e-06	0.000106	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—AKT2—obesity	3.89e-06	0.000106	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IGF1—obesity	3.88e-06	0.000106	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—AKT2—obesity	3.88e-06	0.000106	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CD—obesity	3.74e-06	0.000102	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CD—obesity	3.73e-06	0.000102	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CA—obesity	3.7e-06	0.000101	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SERPINE1—obesity	3.7e-06	0.000101	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CA—obesity	3.69e-06	0.000101	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SERPINE1—obesity	3.69e-06	0.000101	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TYK2—obesity	3.6e-06	9.84e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TYK2—obesity	3.59e-06	9.8e-05	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—RHOA—obesity	3.57e-06	9.75e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—RHOA—obesity	3.56e-06	9.72e-05	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3R1—obesity	3.53e-06	9.65e-05	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NOS3—obesity	3.53e-06	9.65e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NOS3—obesity	3.52e-06	9.62e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3R1—obesity	3.52e-06	9.62e-05	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CA—obesity	3.36e-06	9.2e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CA—obesity	3.35e-06	9.17e-05	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MTOR—obesity	3.26e-06	8.91e-05	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CB—obesity	3.26e-06	8.91e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MTOR—obesity	3.25e-06	8.88e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CB—obesity	3.25e-06	8.88e-05	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—AKT1—obesity	3.03e-06	8.27e-05	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—AKT1—obesity	3.02e-06	8.25e-05	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—IL6—obesity	2.98e-06	8.14e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—IL6—obesity	2.97e-06	8.12e-05	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MMP9—obesity	2.83e-06	7.75e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MMP9—obesity	2.82e-06	7.72e-05	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MAPK8—obesity	2.76e-06	7.53e-05	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—AKT1—obesity	2.75e-06	7.51e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MAPK8—obesity	2.75e-06	7.51e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—AKT1—obesity	2.74e-06	7.49e-05	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—STAT3—obesity	2.52e-06	6.89e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—STAT3—obesity	2.51e-06	6.86e-05	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MYC—obesity	2.34e-06	6.4e-05	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TGFB1—obesity	2.34e-06	6.38e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MYC—obesity	2.33e-06	6.38e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TGFB1—obesity	2.33e-06	6.36e-05	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CA—obesity	1.99e-06	5.43e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CA—obesity	1.98e-06	5.41e-05	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IL6—obesity	1.76e-06	4.81e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IL6—obesity	1.75e-06	4.79e-05	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—AKT1—obesity	1.62e-06	4.44e-05	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—AKT1—obesity	1.62e-06	4.42e-05	CbGpPWpGaD
